METHODS
A prospective, observational, longitudinal, single-center study was
conducted between May 2015 and June 2018. The study included 30 patients
between 2 and 18 years old who underwent allogeneic SCT and received
prophylaxis with micafungin on alternating days after the bone marrow
engraftment phase.